Business Context and Reporting Period
This Form 10-Q is for Brooks Automation, Inc., not Azenta, Inc.; Azenta was the company’s later name. The report covers the three months ended December 31, 2014, the first quarter of fiscal 2015, and was filed February 5, 2015. Brooks provided automation and cryogenic solutions primarily to semiconductor and life-science markets through Brooks Product Solutions, Brooks Global Services, and Brooks Life Science Systems.
The Granville-Phillips business was sold on May 30, 2014 and is presented as a discontinued operation. Prior-period results were revised accordingly.
Key Financial Metrics
| Metric | Q1 FY2015 | Q1 FY2014 |
|---|---|---|
| Revenue | $122.7 million | $117.1 million |
| Gross profit | $39.1 million | $40.9 million |
| Gross margin | 31.8% | 34.9% |
| Operating income (loss) | $(6.5) million | $1.5 million |
| Income (loss) from continuing operations | $(2.7) million | $1.9 million |
| Net income (loss) attributable to Brooks | $(2.7) million | $3.4 million |
| Diluted EPS | $(0.04) | $0.05 |
| Cash flow from operations | $3.0 million | $8.5 million |
- Revenue increased 5%, driven primarily by acquisitions. Product revenue was $99.7 million and services revenue was $23.0 million.
- Operating expenses increased to $45.6 million from $39.4 million, including $2.7 million of restructuring and other charges.
- The company recorded a $3.1 million income-tax benefit, partly attributable to current-period U.S. losses, expiration of foreign tax statutes, and reinstatement of the federal research and development tax credit.
- Cash, cash equivalents, and marketable securities totaled $218.7 million at December 31, 2014, consisting of $77.8 million of cash and cash equivalents, $58.6 million of short-term securities, and $82.3 million of long-term securities.
- Cash and cash equivalents declined $16.4 million during the quarter. Capital lease obligations totaled $8.2 million, including $0.9 million due within twelve months. The company reported no conventional debt balance in the filing.
- The company paid $6.7 million in dividends and declared a subsequent quarterly dividend of $0.10 per share.
Material Changes Versus the Prior Comparable Period
- Revenue increased $5.7 million, or 5%, but gross profit declined $1.8 million and gross margin fell 310 basis points.
- Product Solutions revenue rose 2% to $82.9 million, while Global Services revenue declined slightly to $23.2 million. Life Science Systems revenue increased 37% to $16.7 million.
- Acquisitions contributed approximately $10.8 million of revenue, including $7.2 million from DMS and $3.6 million from FluidX. Semiconductor customer demand declined, offsetting part of the acquisition-related growth.
- Life Science Systems gross margin fell to 22.2% from 37.4%, primarily because of project cost-estimate revisions, premium installation and freight costs, and $1.0 million of acquisition-related inventory step-up charges.
- Product Solutions gross margin declined to 32.5% from 34.9%, reflecting Polycold manufacturing-transition costs, higher warranty costs, and acquisition-related inventory charges. Global Services gross margin improved to 36.5% from 33.6%.
- Restructuring charges increased to $2.7 million from $0.7 million, primarily for workforce reductions and facility-exit costs associated with manufacturing outsourcing and DMS integration.
- Prior-year results included $1.6 million of after-tax income from discontinued operations; the current quarter included none.
- Equity-method results shifted from $0.7 million of income to $0.5 million of loss, including a $0.7 million impairment related to the planned dissolution of the Yaskawa Brooks Automation joint venture.
Outlook, Risks, Contingencies, and Unusual Items
- Management stated that available resources were adequate for planned working-capital and capital-expenditure needs for the next twelve months, but noted that semiconductor-market cyclicality and global economic uncertainty make longer-term liquidity needs difficult to predict.
- Semiconductor capital-equipment demand remains a key exposure; shipments to semiconductor customers represented approximately 50% of consolidated revenue. One customer accounted for 13% of revenue in both comparable quarters.
- Management intends to continue quarterly dividends but may reduce, delay, or cancel them during a severe cyclical downturn.
- The company completed the $15.4 million acquisition of FluidX on October 1, 2014. The preliminary purchase-price allocation remained subject to finalization, and FluidX generated $3.6 million of revenue and a $0.5 million net loss in the quarter.
- The company funded BioCision with $2.5 million in December 2014 and another $2.5 million after quarter-end. The BioCision securities and warrant are Level 3 fair-value instruments subject to significant valuation assumptions.
- Letters of credit totaling approximately $21.3 million supported customer advances and other performance obligations. Management did not expect them to be called, but they could be called if contractual requirements are not met.
- The company had approximately $1.0 million of estimated fair value remaining on a previously impaired note receivable from a strategic partner; recovery depends on the borrower’s future cash flows and collateral value.
- The company expected the Yaskawa joint-venture dissolution to be completed during the second quarter of fiscal 2015. A subsequent agreement provided for the company’s Japanese subsidiary to acquire certain YBA assets, with the transaction expected in March 2015.
- Legal proceedings existed in the ordinary course of business. Management did not believe they would materially affect consolidated results, while acknowledging that outcomes are inherently uncertain.
- Foreign sales represented approximately 35% of total sales. Management estimated that a hypothetical 10% currency movement would change net income by approximately $0.9 million.
Important Facts for Investors to Verify
- Entity identity: Confirm that this historical Brooks Automation filing is the intended source for the Azenta request.
- Margin recovery: Assess whether Life Science Systems project-cost issues, acquisition inventory step-ups, warranty costs, and Polycold transition costs were temporary or structural.
- Acquisition performance: Verify FluidX and DMS integration progress, final purchase-price allocations, goodwill, and post-acquisition profitability.
- Liquidity and capital allocation: Reconcile the decline in cash with acquisitions, BioCision funding, dividends, securities sales, capital expenditures, and lease obligations.
- Semiconductor cyclicality: Monitor customer concentration, semiconductor equipment demand, and the potential effect on revenue and operating leverage.
- Contingent exposures: Review the letters of credit, tax audits and unrecognized tax benefits, legal proceedings, BioCision valuation, and the impaired strategic-partner note.
- Discontinued operations: Ensure comparisons exclude Granville-Phillips consistently and do not treat its prior-period contribution as ongoing revenue or earnings.